UTMB Center for Addiction Research/Innovations in Molecular Therapeutics

Therapeutic Approaches: Small Molecules, Vaccines, Biomarkers

Therapeutic Areas of Expertise: Metabolic Disorders, Neurological Disorders, Oncology, Psychiatric Disorders, Pain

Center/Program Highlights: The UTMB Center for Addiction Research Molecular Therapeutics Initiative at the University of Texas Medical Branch (UTMB) is leveraging institutional target-based discovery, disease-specific knowledge and specialized core technologies toward new molecular therapeutics for drug addiction and related chronic health disorders. The Molecular Therapeutics Initiative is integrated into the UTMB Clinical and Translational Sciences Award and focuses on the development of novel small molecules, peptides and vaccines as well as biomarker discovery. Our translational team encompasses investigators and mentees that cross the barriers of technologies (chemistry, cell biology, animal models, clinical science, structural biology), biomedical disorder (addictions, cancer, infectious diseases, neurodegeneration, etc.) and regional institutions (UTMB, MD Anderson, University of Houston, University of Texas Health Science Center at Houston, University of Texas at Austin). We are currently focused on generation of a portfolio of molecules and tool compounds for validation of new targets, hit to lead optimization and preclinical evaluation.

Sources of Funding: Federal/State, Philanthropy, Industry Partnerships, Disease Foundations, University

Industrial Partnerships: Arena, Acadia


Institutional Affiliation(s): The University of Texas Medical Branch, University of Houston, MD Anderson, University of Texas Health Science Center at Houston, University of Texas at Austin

301 University Boulevard
Texas, 77550
United States

Center/Program Start Date: 2010

Number of Employees: 30